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Temporary regression of recurrent squamous cell carcinoma of the head
and neck is achieved with a low but not with a high dose of recombinant
interleukin 2 injected perilymphatically
G. Cortesinal, A. De Stefani', E. Galeazzil, G.P. Cavallol, F. Badellino3, G. Margarino3,
C. Jemma2 & G. Forni2,4
'11 Clinica Otorinolaringoiatrica and 'Centro CNR di Immunogenetica ed Istocompatibilitita' dell'Istituto di Microbiologia,
Universita' di Torino, Turin, Italy; 3Istituto Scientifico Tumori, Genoa, Italy.
Summary The efficacy of ten daily injections of 500 or 500,000 U of recombinant interleukin 2 (IL-2) day-'
given 1.5 cm from the insertion of the sternocleidomastoid muscle on the mastoid was evaluated in 31 patients
with recurrent head and neck squamous cell carcinoma. No toxic effects were noted. One complete response
(CR) and three partial responses (PRs) were observed in the 16 patients who received 500 U of IL-2, whereas
the higher dose was not effective. The CR was recorded in one of the seven patients with a oropharyngeal
recurrence. Partial responses were obtained in 1/5 patients with hypopharyngeal recurrences, in 1/5 patients
with oral cavity recurrences and 1/7 patients with laryngeal recurrences. The duration of the responses was
3-5 months and additional courses of ten injections of IL-2 had no further effect.
Experimental data from murine models have shown that
tumour-immunosuppressive capabilities can be drastically
modified by the availability of exogenous IL-2 at the tumour
growth site or around its draining lymph nodes (Colombo et
al., 1992). As IL-2 plays a crucial immunoregulatory role, its
local presence can counteract tumour-borne immunosuppres-
sion and help to initiate a complex and multicell-mediated
anti-tumour response. The efficacy of this host reaction is
related to the presence and quantity of tumour-infiltrating
leucocytes and the amount of IL-2 injected. Very low doses
are effective, whereas no improvement, or even a loss of
efficacy, takes place when a critical threshold is exceeded
(Forni et al., 1985; Bosco et al., 1990). In this IL-2-activated
tumour inhibition, the mechanisms of non-specific immunity
appear to be prominent initially, whereas a tumour-specific
delayed-type hypersensitivity and immune memory are estab-
lished following tumour rejection (Forni et al., 1987).
In the light of these experimental findings, we have set up
a programme to study the effectiveness of local IL-2 adminis-
tration in the management of patients with recurrent head
and neck squamous cell carcinoma (rH&NSCC). The goals
are first to activate a reaction strong enough to affect tumour
progression and then to elicit a long-lasting immune memory,
thus setting the scene for a novel immunotherapeutic app-
roach. It was felt that these tumours were a rational choice,
since they are surrounded by the body's most conspicuous
lymph node network and can readily be manipulated from
outside through surgical infiltration, both around the tumour
itself and in the draining lymph nodes (Cortesina et al.,
1988).
The possibility of initiating local reactivity acquires parti-
cular importance in rH&NSCC since these tumours display
local growth, a tendency to form local recurrences and
regional lymph node metastais. Moreover, there is a direct
correlation between the degree of immune suppression and
the severity of the prognosis. On the other hand, the very
strong immunosuppressive potential of rH&NSCC makes a
local immune reactivity difficult to achieve (Cortesina et al.,
1982; Wolf et al., 1986).
In an initial trial, ten patients with inoperable rH&NSCC
received a course of ten daily injections of 200 U of natural
IL-2 (nIL-2) purified from the supernatant of the Jurkat cell
line. A complete (CR) or partial response (PR) was observed
in six patients. Decrease and disappearance of neoplastic
lesions were documented clinically, radiologically and histo-
logically, but relapses supervened after a disease-free interval
of 3-5 months (Cortesina et al., 1988).
The present study reports the effects of repeated administ-
ration of 500 and 500,000 U of recombinant (r) IL-2 around
tumour-draining lymph nodes in 31 rH&NSCC patients.
Materials and methods
Trial design
The trial was conducted on patients with rH&NSCC to
assess the therapeutic effect of 500 or 500,000 randomly
assigned units (U) of rIL-2 (Glaxo, Geneva, Switzerland)
injected around tumour-draining lymph nodes. The low dose
of 200 U used in the previous trials (Cortesina et al., 1988,
1991) was increased to 500 U to improve the stability of the
recombinant protein and ensure more precise standardisation
of the preparations used in the two centres engaged in this
study. The 500,000 U dose was utilised since this range has
been found effective in local tumour therapy (reviewed by
Pericle et al., 1992) and intralesional therapy of head and
neck tumours (Rivoltini et al., 1990). During an accrual
period of 24 months, 31 rH&NSCC patients, already treated
by surgery, radiotherapy or chemotherapy for possible prior
salvage, were recruited (20 at the Otorhinolaryngology Clinic,
University of Turin, 11 at the Istituto Scientifico Tumori,
Genoa, Italy). In cases of severe kidney and liver insufficiency,
chemotherapy was not considered for salvage. All patients
gave their prior signed consent in accordance with the
Recommendations of the Declaration of Helsinki (1985).
The inclusion criteria were: biopsy or fine-needle biopsy
histological confirmation of recurrences of squamous cell
carcinoma located anywhere in the upper airways and diges-
tive tract, including the oral cavity, oropharynx, hypo-
pharynx, rhinopharynx and larynx, not open to conventional
management and measurable in the two major diameters;
Karnofsky index >70%; serum bilirubin and creatinine in
the normal range; expected survival of at least 4 months; age
range 18-75 years; ipsi- or contralateral intact cervical
lymph nodes. The exclusion criteria were: bilateral radical or
functional neck dissection; chemotherapy, immunotherapy,
surgery or radiotherapy in the previous 4 weeks; ongoing
systemic infection or other significant pathological condi-
tions; treatment with IL-2 in the previous 3 months; presence
of cerebral metastases; treatment with corticosteroids or non-
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Table I Patient characteristics and results
Patient Primary carcinoma
no. Location TNM
1 Oral cavity T3NA
2 Larynx
3 Larynx
4 Oropharynx
5 Oropharynx
6 Parotid gland
7 Nasopharynx
8 Nasopharynx
9 Larynx
10 Parotid gland
11 Hypopharynx
12 Oropharynx
13 Parotid gland
14 Larynx
15 Oropharynx
16 Larynx
17 Oral cavity
18 Hypopharynx
19 Hypopharynx
20 Oral cavity
21 Hypopharynx
22 Larynx
23 Oral cavity
24
25
26
Paranasal sinus
Larynx
Oropharynx
27 Oral cavity
28 Hypopharynx
29 Oropharynx
30 Oropharynx
31 Larynx
T3No
T4N3
T3N2
T2N,
T2NO
T3N,
ToN3
T4No
T4N2
T3N,
T2N,
T2N,
T3NA
T4NA
T3N2
T2N,
T3N2
T3N
T2N1
T3N3
T4NA
T4No
T3N,
T3No
T3N,
T2N,
T4N3
T2N,
T3No
T3N2
Therapy
Surgery
Radiation
Chemotherapy
Surgery
Radiation
Radiation
Chemotherapy
Surgery
Radiation
Radiation
Surgery
Radiation
Chemotherapy
Radiation
Chemotherapy
Radiation
Chemotherapy
Surgery
Radiation
Radiation
Chemotherapy
Radiation
Chemotherapy
Radiation
Surgery
Radiation
Chemotherapy
Surgery
Radiation
Radiation
Chemotherapy
Surgery
Radiation
Surgery
Radiation
Chemotherapy
Radiation
Chemotherapy
Radiation
Chemotherapy
Radiation
Chemotherapy
Radiation
Chemotherapy
Radiation
Chemotherapy
Surgery
Radiation
Chemotherapy
Radiation
Chemotherapy
Radiation
Chemotherapy
Surgery
Radiation
Chemotherapy
Surgery
Radiation
Radiation
Chemotherapy
Surgery
Radiation
Radiation
Chemotherapy
Surgery
Radiation
Chemotherapy
Recurrence IL-2 treatment
Location Size (cm) Dose (IU) Results
Primary tumour 3 x 2 500 MR
Cervical lymph nodes 10 x 5
Primary tumour
Primary tumour
Cervical lymph nodes
Primary tumour
Cervical lymph nodes
Primary tumour
Primary tumour
Cervical lymph nodes
Cervical lymph nodes
Skin peritracheostomy
Primary tumour
Cervical lymph nodes
Skin
Primary tumour
Primary tumour
Cervical lymph nodes
Primary tumour
Cervical lymph nodes
Cervical lymph nodes
Cervical lymph nodes
Primary tumour
Primary tumour
Primary tumour
Primary tumour
Primary tumour
Cervical lymph nodes
Primary tumour
Cervical lymph nodes
Primary tumour
Cervical lymph nodes
Primary tumour
Cervical lymph nodes
Primary tumour
Primary tumour
Cervical lymph nodes
Primary tumour
Cervical lymph nodes
Primary tumour
Cervical lymph nodes
Primary tumour
Primary tumour
Cervical lymph nodes
2 x 2
7.5 x 5a
4 x 4
6 x 2.5
2 x 2
4 x 5
4 x 6
6 x 6
5 x4
7 x 7a
2 x 2
2.5 x 4
4 x 4
3 x 3
2.5 x 3
3.5 x 4
4 x 5
1.5 x 2.5
3 x 3
2 x 2.5
4 x 4
3 x 2
3 x 3
5 x 6a
3.5 x 3
3 x 4
5 x 8a
2.5 x 3
3 x 3
3.5 x 4
3.5 x 4
3 x 4
2.5 x 2.5
3 x 4
3.5 x 3.5
4 x 4
5 x4
500
500,000
500,000
PR
MR
NR
500 CR
500 MR
500,000
500
500,000
500,000
NR
NR
NR
NR
500 PR
500 NR
500,000 NR
500,000
500
500,000
500
500
500
500,000
500
500,000
MR
MR
NR
PR
NR
MR
NR
MR
NR
500 NR
500,000
500,000
500,000
500,000
500
500
500
500,000
NR
NR
MR
MR
MR
MR
MR
NR
aThis measure includes primary tumour and lymph nodes.
steroidal anti-inflammatory drugs (except paracetamol) or
any other drug during the experiment.
Patient evaluation
General assessment prior to treatment included history and
physical examination, haematological and blood chemistry
examinations, urine examination, ECG and chest radio-
graphy. Other clinical examinations were undertaken to
assess suspected sites of metastasis. Tumour status was deter-
mined by CT scan. Tumour size was expressed as the product
of the two major perpendicular diameters, or as the sum of
the products in the case of multiple lesions. Toxicity was
evaluated according to the WHO criteria. Responses were574 G. CORTESINA et al.
Figure 1 Recurrence of a radiation-treated tumour of the left tonsillar fossa (patient 5). Left: The day before the beginning of IL-2
course. Right: Disappearance of the tumour 1 month after IL-2. T, tongue; PA, palatine arch; C, cheek. The arrowheads indicate
the borders of the tumour mass.
Figure 2 Recurrence of a tumour of the lateral floor of the mouth previously treated by surgery and radiotherapy (patient no. 17).
Left: The day before the beginning of the IL-2 course. Right: Decrease and necrosis (white area) of the tumour 1 month after IL-2.
T, tongue; C, cheek. The arrowheads indicate the border of the tumour mass.
rated as follows: CR, if the tumour was no longer evident;
PR, if the sum of the products of the two major diameters of
all lesions was reduced by more than 50%; minor response
(MR), if the reduction was less than 50% but greater than
25%; no response (NR), absence of both response and pro-
gression; progression of the disease, appearance of new
lesions or >25% increase in volume of one or more
measurable lesions. Tumours were measured once a week by
two operators independently, and the average value is
reported. No significant differences in evaluation were found.
Size was determined by CT or by physical examination with
fibre-optic visualisation where necessary. A response wasIL-2 IN HEAD AND NECK CARCINOMAS 575
considered complete, partial or minor when the same
measurements were found for two successive weeks and then
lasting 1 month.
Treatment plan
Each patient was randomly assigned a dose of 500 or
500,000 IU of rIL-2 per day for administration diluted in
1 ml of physiological saline supplemented with 10% human
serum albumin (HSA) (Institut Merieux, Lyon, France) to
stabilise rIL-2, which is a markedly hydrophobic protein, and
improve its absorption via the lymphatic system (Bocci et al.,
1985). Inoculation was performed in the morning with a 26
gauge needle at a depth of 15 mm in the anterior margin of
the sternocleidomastoid muscle at 15 mm from its insertion
on the mastoid (Cortesina et al., 1988). The injections were
performed on the same side as the recurrent tumour when
draining lymph nodes were still present, and contralaterally
when only contralateral lymph nodes were present, as in
patients who had undergone unilateral neck dissection for
oral cavity, oropharyngeal or parotid gland tumours. The
patient was kept under observation for at least 30 min in the
event of day-hospital administration. The ten daily injections
were followed by an interval without treatment until day 40.
A further three courses of ten injections were given at 30 day
intervals in the absence of a CR. A Karnofsky index > 70%
was required prior to their commencement. Haematological
and blood chemistry examinations were performed on day 0,
day 10 and day 40. To ensure that injections were performed
in the same way in both centres, the first patient in each
location was treated by the same operator.
Results
The results are reported in Table I. The CR was observed in
a patient (no. 5) who had received radiotherapy for an
oropharyngeal tumour. On recurrence after a 9-year disease-
free interval, he refused chemotherapy and commenced the
rIL-2 treatment. After 10 days, the tonsillar fossa began to
be covered with a layer of necrosis. This then gradually
disappeared to reveal smooth clean mucosa after I month
(Figure 1). The four MR patients (nos. 15, 26, 29 and 30)
were bearers of more extensive and more heavily treated
recurrent oropharyngeal tumours who received IL-2 1 year or
longer after the end of their previous therapy. MR was
clearly evident after 30 days.
One PR and two MRs were obtained in the five patients
with oral cavity tumours. The PR was observed in a patient
(no. 17) with recurrence of a lateral tumour of the floor of
the mouth, treated surgically and with radiotherapy 3 years
earlier. The first recurrence appeared after an 18-month
disease-free interval and was treated with chemotherapy for 6
months. The second recurrence appeared after a further year
and was treated with IL-2. Necrosis of the tumour surface
was noted after 12 days, and 60% reduction in size was
reached after 60 days (Figure 2). The two MR patients
(nos. 1 and 27) presented recurrences at the primary tumour
site and in the cervical lymph nodes. Conventional manage-
ment had been terminated 9 months prior to IL-2 therapy. A
more than 50% reduction in size of the primary site recur-
rence was obtained in both cases after 20 days. The lymph
node enlargement, however, was unaffected, and hence the
results were classified as MR.
One PR and three MRs were found in five hypopharynx
recurrences. The PR was observed in a patient (no. 11) who
had received combined radio- and chemotherapy. The recur-
rence treated with IL-2 occurred after a 1 year disease-free
interval. Direct laryngoscopy revealed its almost complete
disappearance after 30 days. The MR patients (nos. 19, 21
and 28) had not been treated for 7 months. MRs were noted
after 20 days.
One PR and three MRs were obtained in eight patients
with laryngeal recurrences. The PR was observed in a patient
(no. 2) who had undergone total laryngectomy for the
primary tumour and radiotherapy for the first recurrence.
The second recurrence (treated with IL-2) appeared after an
8 month disease-free interval. PR with improved deglutition
was achieved after 15 days. The MRs were observed after 20
days in a patient (no. 3) 6 months after the conclusion of
chemotherapy, and another (no. 14) 2 years after
radiotherapy. The last MR was noted in one of the two
subjects with recurrent parotid gland carcinoma. This patient
(no. 6) had received various ineffective treatments. IL-2 was
begun 6 months after the termination of chemotherapy. Flat-
tening of the tumour and a >40% reduction in its size were
observed after 25 days.
Clinical responses were nearly always preceded by im-
provement of the functional impairment caused by tumour
infiltration of the upper respiratory-digestive organs. Pain
appeared to increase to a slight degree at first, though it
diminished or disappeared when tumour shrinkage began.
No major toxic effects were noted in both IL-2 dose groups.
Occasional fever episodes (more pronounced in patients
receiving the higher dose) were easily controlled with
paracetamol. In some cases, reduction of the tumour mass
was accompanied by the almost complete disappearance of
the necrotic component. Responses lasted 3-5 months and
further IL-2 courses were ineffective (data not shown).
Discussion
Perilymphatic administration of low-dose courses of rIL-2 is
a simple manoeuvre, devoid of local and systemic side-effects.
It led to one CR and three PRs in 31 patients (13%) with
rH&NSCC. MRs are reported for interest only, since these
carcinoma recurrences progress rapidly and fail to respond to
standard therapy, and are omitted in the overall evaluation
of the results. All these findings are in line with those of our
previous studies conducted with nIL-2 (Cortesina et al., 1988,
1991). Unfortunately, the brief duration of all responses and
the ineffective treatment of further relapses observed in this
and in our previous study point to the development of
resistance to IL-2.
One interesting finding in this study is that doses of 500 U
of rIL-2 infused regionally are effective, whereas 500,000 U
doses are not. Interestingly, in a similar study using intra-
arterial rIL-2 administration in rH&NSCC patients, the res-
ponses seen were at low dose of IL-2 in comparison with the
high dose (Gore et al., 1992), while in experimental models
low doses are often more effective inducers of local reactivity
(Forni et al., 1985, 1987; Bosco et al., 1990). However, the
number of patients is too small for significant comparison.
The efficacy of IL-2 treatment may be markedly influenced
by the size of the recurrences and their histological
features.
The best results in this and our previous study were
obtained in small oropharyngeal recurrences. An encouraging
susceptibility to IL-2 management was also displayed by
hypopharyngeal tumours, as shown initially by marked
regression of dysphagia and confirmed by endoscopy. The
four responses were in small recurrences in the primary
tumour site as opposed to the lymph nodes. A reason is thus
found for the failure of nasopharyngeal carcinomas to re-
spond to either nIL-2 or rIL-2, since their recurrences are
usually located in the lymph nodes. In the case of lymph
node and combined tumour site plus lymph node recurrence,
MRs only were found.
The temporary activity of IL-2 against small rH&NSCC
recurring at the site of the primary tumour would appear to
be confirmed. In effect, the four responses were obtained in
tumours that seemed unlikely to respond as they had already
been pretreated and no longer responded to conventional
therapy. The efficacy of the immune reactivity becomes mar-
ginal in these conditions. Patients with rH&NSCC display
marked immunosuppression that may impair the establish-
ment of systemic reactivity (Lundy et al., 1974; Cortesina et
al., 1982; Morra et al., 1984; Wolf et al., 1986). The fact that
a biological therapy was also able to induce 12 MRs is a576 G. CORTESINA et al.
further point of interest. Our previous findings with nIL-2
(Cortesina et al., 1988, 1991) and present findings with rIL-2
display some common features: good susceptibility on the
part of small recurrences in the primary tumour site,
especially the oropharynx; the absence of side-effects; the
functional effectiveness of the administration route; and the
inverse proportion between tumour mass and clinical re-
sponse. These features suggest that small primary head and
neck tumours before surgery and the minimal residual disease
that follows surgery are more suitable settings for
locoregional immunotherapy. The aim is to include the injec-
tion of IL-2 around tumour-draining lymph nodes in multi-
disciplinary strategies designed to improve the prognosis of
patients with H&NSCC low 5-year survival percentages.
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